Literature DB >> 16334162

Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer.

Hideki Kawai1, Akira Ishii, Kiyotada Washiya, Toshiko Konno, Hiroto Kon, Chiharu Yamaya, Iwao Ono, Junichi Ogawa.   

Abstract

BACKGROUND: The aim of the present study was to determine the prognostic significance of the combined overexpression of epidermal growth factor receptor (EGFR) and estrogen receptor a (ER-alpha) in non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: An immunohistochemical assessment of EGFR and ER-alpha expression was carried out in tumor specimens from 122 consecutive NSCLC patients after surgery.
RESULTS: Of the 122 tumors examined, 57 (46.7%) overexpressed EGFR, 63 (51.6%) overexpressed ER-alpha, while 33 (27%) overexpressed both EGFR and ER-alpha. Univariate analyses showed that the overexpression of EGFR or ER-alpha correlated with the histological grade (p = 0.01 and p = 0.03, respectively) and a poorer prognosis (p = 0.007), while overexpression of ER-alpha also correlated with smoking (p = 0.02). Multivariate analysis showed the combined overexpression of EGFR and ER-alpha to be an independent indicator of poorer prognosis (p = 0.0006).
CONCLUSION: The combined overexpression of EGFR and ER-alpha in NCLSC patients is predictive of poor outcome and, thus, represents a valuable prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16334162

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  27 in total

Review 1.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

Review 2.  Estrongenic steroid hormones in lung cancer.

Authors:  Jill M Siegfried; Laura P Stabile
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

Review 3.  Minireview: Familiar Faces in Unfamiliar Places: The Emerging Role of Nuclear Receptors in Lung Cancer.

Authors:  Paul Yenerall; Ralf Kittler
Journal:  Mol Endocrinol       Date:  2015-10-20

4.  Comparative assessment of the estrogen receptor β expression in the tissues of non-small cell lung carcinoma and lung metastases of tumors of other primary localizations.

Authors:  T A Bogush; A S Shaturova; E A Dudko; E A Bogush; B E Polotsky; S A Tyulandin; M I Davydov
Journal:  Dokl Biochem Biophys       Date:  2014-03-16       Impact factor: 0.788

Review 5.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

6.  Estrogen receptor signaling in lung cancer.

Authors:  Jill M Siegfried; Pamela A Hershberger; Laura P Stabile
Journal:  Semin Oncol       Date:  2009-12       Impact factor: 4.929

Review 7.  Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer.

Authors:  Hideki Kawai
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Association of estrogen receptor α gene PvuII and XbaI polymorphisms with non-small cell lung cancer.

Authors:  Huai-Lu Chang; Yu-Jen Cheng; Chung-Kuang Su; Meng-Chih Chen; Fu-Hsin Chang; Fu-Gong Lin; Li-Feng Liu; Shyng-Shiou F Yuan; Ming-Chih Chou; Chien-Fu Huang; Chi-Chiang Yang
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

9.  Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.

Authors:  Maria G Raso; Carmen Behrens; Matthew H Herynk; Suyu Liu; Ludmila Prudkin; Natalie C Ozburn; Denise M Woods; Ximing Tang; Reza J Mehran; Cesar Moran; J Jack Lee; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

10.  Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed?

Authors:  O Ayeni; A Robinson
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.